WO1991013652A1 - Apparatus for treating abnormal pigmentation of the skin - Google Patents

Apparatus for treating abnormal pigmentation of the skin Download PDF

Info

Publication number
WO1991013652A1
WO1991013652A1 PCT/US1991/001714 US9101714W WO9113652A1 WO 1991013652 A1 WO1991013652 A1 WO 1991013652A1 US 9101714 W US9101714 W US 9101714W WO 9113652 A1 WO9113652 A1 WO 9113652A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
laser
light guide
skin
wavelength
Prior art date
Application number
PCT/US1991/001714
Other languages
French (fr)
Inventor
Horace Furumoto
Harry L. Ceccon
Christopher J. Jones
Kathleen Mcmillan
Original Assignee
Candela Laser Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23959698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991013652(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Candela Laser Corporation filed Critical Candela Laser Corporation
Publication of WO1991013652A1 publication Critical patent/WO1991013652A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/203Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452Skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00452Skin
    • A61B2018/00458Deeper parts of the skin, e.g. treatment of vascular disorders or port wine stains
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/067Radiation therapy using light using laser light

Definitions

  • a subject's skin may have pigmentation abnormalities due to vascular lesions, naturally occuring pigmented lesions, or tattoos.
  • Vascular lesions such as port wine stain birthmarks, telangiectasia and hemangiomas are caused by the abundance of enlarged blood vessels.
  • Pigmented lesions are non-vascular disfigurements of the skin caused by an abnormally high concentration of melanin in localized areas of the skin.
  • Such pigmented lesions include freckles, age or liver spots, cafe' au lait birthmarks, lentigines , nevi , melanomes , nevus of Ota and lentigo maligna.
  • Tattoos may be divided into two categories, including self-inflicted or traumatic tattoos. Traumatic tattoos are created during accidents which cause a scrape or abrasion such that a foreign material becomes imbedded in the skin.
  • Melanin an endogenous cutaneous pigment which is most concentrated in the basal layer of the epidermis, 0 has an absorption spectrum that is highest in the ultraviolet range and gradually diminishes toward the infrared.
  • Melanosomes are melanocyte-specific organelles densely packed with melanin. They vary in size according to their genetic origin; black skin typically containing 5 larger melanosomes than lightly pigmented, white skin. Based on melanosome size, the calculated thermal relaxation time for these organelles is around 10 nsec. On the other hand, melanocytes are approximately 7 ⁇ m in diameter, with thermal relaxation times around 1 ⁇ sec. 0 Thermal relaxation time in both instances is defined as the time taken for a structure to cool to 50% of its peak temperature immediately after laser exposure.
  • an apparatus produces a plurality of pulsed beams of laser radiation for the treatment of epidermal and dermal pigmentation abnormalities of the skin.
  • An apparatus capable of providing one of two beams of different wavelengths is believed to be sufficiently effective for the majority of cases in therapeutic dermatology and plastic surgery involving treatment of non-vascular pigmentation abnormalities.
  • the apparatus comprises a first pulsed laser producing a first beam principally for the treatment of epidermal pigmentation abnormalities and a second pulsed laser producing a second beam principally for the treatment of dermal pigmentation abnormalities.
  • the first laser is pulsed dye laser supported by a dye circulation system and the second laser is an alexandrite laser.
  • the two lasers are coupled to a common power supply and storage system.
  • the lasers are excited by a flashlamp means which may comprise a single coaxial flashlamp for exciting both lasers or a pair of coaxial flashlamps for separately exciting each laser.
  • the first laser is used to excite the second laser in a laser excited configuration.
  • the first laser is preferrably a flashlamp excited pulsed dye laser and the second laser is preferrably an alexandrite laser.
  • specific laser parameters are established to obtain effective treatment of epidermal and dermal pigmentation abnormalities while minimizing damage to normal pigmented cells.
  • effective treatment of epidermal lesions with minimal damage has been obtained with a first laser having a wavelength of about 500 nm, a pulse duration of about 500 nsec, and fluence
  • wavelength of the first beam should be less than 600 nm. Due to known problems of mutagenesis, the wavelength should not be less than 345 nm.
  • 2 of the first beam may range from 1 to 10 J/cm at the skin through the full range of wavelengths , but is 2 preferably within the range of 2 to 4 J/cm for 504 nm light. Pulse durations approaching 1 /-sec may be used but at 1 / -sec recurrence is expected. Shorter pulse durations should minimize damage to normal tissue.
  • a window is created in the epidermis using the above defined laser parameters and the deeper cells are treated with the second laser having parameters specific to those cells. More specifically, it is expected that effective treatment with minimal damage may be obtained with the second laser having a wavelength of about 750 nm, a pulse duration of
  • the fluence at the skin for the second beam may
  • the spotsize may range from about 2 to 5 mm diameter, but preferrably it is about 3 mm diameter.
  • the longer wavelengths are required to penetrate to depths associated with the location of dermal pigmentation abnormalities.
  • treatment is adminstered with a delivery system which is manipulated to deliver radiation to illuminate an area of a subject's skin.
  • the dual laser system requires pulse durations on the order of tens to hundreds of nanoseconds for potentially high intensity pulses.
  • the delivery system must be capable of transmitting high peak intensity pulses with low losses and must be flexible for convenience of use. 6 -
  • one embodiment of the preferred delivery system of the present invention comprises a pair of flexible liquid core light guides having sufficient diameter to efficiently transmit high peak power intensity pulses of wavelengths between 345 and 1100 nm from the dual laser system. More specifically, a first liquid core light guide delivers the first beam of laser radiation of wavelength between 345 and 600 nm, fluence
  • the first liquid core light guide has a liquid core comprising an aqueous inorganic salt solution within a flexible cladding which facilitates the transmission of laser radiation of wavelengths between 345 and 600 nm.
  • the core diameter may be between 3 and 10 mm and preferrably about 3 mm such that the first guide is capable of transmitting high peak intensity pulses.
  • the liquid within the first guide does not effectively transmit radiation of wavelengths between 600 and 1100 nm due to the presence of chemical bonds involving hydrogen which significantly attenuate the radiation.
  • the second liquid core light guide delivers the second beam of laser radiation of wavelength between 600
  • the second guide has a liquid core comprising a liquid and housed within a flexible cladding.
  • the liquid has a molecular structure characterized by the absence of chemical bonds which would cause absorption between wavelengths 600 and 1100 nm.
  • the liquid is non-hydrogenous and comprises halogenated compounds.
  • the liquid comprises halocarbons such as tetrachloroethylene or carbon tetrachloride , or a solution of inorganic salts in deuterium oxide.
  • the index of refraction for the liquid is greater than the index of refraction for the cladding.
  • the liquid core of the second light guide has a diameter between 3 and 10 mm and preferrably about 5 mm such that the second guide is capable of transmitting high peak intensity pulses.
  • Another embodiment of the preferred delivery system of the present invention comprises a flexible liquid core light guide for efficiently transmitting high peak power intensity pulses of wavelengths between 345 and 1100 nm from the dual laser system.
  • the second light guide comprises a liquid capable of delivering laser radiation from the first laser for treatment of epidermal pigmentation abnormalities and from the second laser for treatment of dermal pigmentation abnormalities.
  • the light guide is coupled to both lasers and delivers radiation from the particular laser being employed for treatment.
  • Fig. 1 illustrates a dual laser system with separate delivery systems.
  • Fig. 2 is an enlarged perspective view of the handpiece of Fig. 1.
  • Fig. 3 is a block diagram of a preferred embodiment dual laser system.
  • Fig. 4 is a block diagram of another preferred embodiment dual laser system.
  • Fig. 5 is a block diamgram of yet another preferred embodiment dual laser system.
  • Fig. 6 is a cross-sectional view of a liquid core light guide of Fig. 1.
  • Pigmentation abnormalities may be removed from the skin by lasers provided that the lasers have the proper characteristics based on the principles of selective photothermolysis. These principles require the proper selection of wavelength (or color) of the laser to maximize absorption within the targeted lesion and minimize absorption by the surrounding normal tissue, organs or organelles. Selective photothermolysis also requires the precise selection of pulse duration of the laser beam which is determined by the thermal relaxation time of the target. Pulse duration should be shorter than the thermal relaxation so that only the targeted material is heated and the surrounding tissue is unaffected.
  • Pigmented lesions have broad band absorption characteristics with high absorption at shorter wavelengths (blue-violet) arid decreasing monotonically to higher wavelengths (red). Additionally, it has been shown that shorter wavelength (blue-green) lasers treat superficial pigmented lesions better than longer wavelength (red) lasers. On the other hand, longer wavelength (red) lasers are more effective for treating dermal pigmentation abnormalities including deeper pigmented lesions and tattoos. However, it has been demonstrated that the long wavelength ruby red laser is 9 -
  • 10 system 12 provides two pulsed beams of laser radiation having distinct wavelengths which may be employed for the treatment of epidermal and dermal pigmented lesions of the skin (see Fig. 1). Although a laser system producing more than two different wavelength beams is within the
  • a delivery system 13 is coupled to the laser system 12 and delivers the two laser beams to a pigmented region of the skin.
  • the first laser beam is delivered through a first light guide 14 to a handpiece 16 and second laser beam is delivered through a
  • the delivery system may comprise only the second light guide 15 and the handpiece 17 (Fig. 5).
  • both laser beams are coupled to the guide 15 which delivers either beam to the skin for
  • a preferred handpiece illustrated in Fig. 2, is model number 7040-00-6231 sold by Candela Laser Corporation.
  • Two lenses in the handpiece image the distal end of the guide to a larger spot adjacent to the end of a positioning extension 18.
  • the spotsize can be varied.
  • the spotsize may be between 2 and 5 mm diameter and is preferrably about 3 mm diameter.
  • the laser system 12 comprises a pair of laser systems 20 and 22.
  • the laser systems comprise a pair of flashlamp excited pulsed lasers 21 and 23 having a common power supply/storage system 24.
  • the lasers are excited by a flashlamp means which may comprise a single coaxial flashlamp (not shown) or a pair of coaxial flashlamps 26 and 27 for separately exciting the first and second laser 21 and 23 respectively.
  • the first laser 21 is a pulsed dye laser having a dye circulation system 28 and the second laser 23 is an alexandrite laser.
  • both lasers may be pulsed dye lasers with separate circulation systems.
  • one or both of the laser systems 20 and 22 may comprise any non-dye pulsed laser system such as a solid state laser.
  • a first laser system 20 is arranged to excite a second laser system 22 in a laser-excited configuration.
  • the first laser 20 is a flashlamp excited pulsed dye laser supported by a dye circulation system 28 and the second laser 32 is an alexandrite laser.
  • the pair of laser systems 20 and 22 are coupled by an optical coupler 38 to the delivery system 13 comprising a single light guide 17.
  • the laser systems 20 and 22 may comprise any combination of the following lasers to provide a short wavelength beam and a long wavelength beam of laser radiation.
  • the first laser may be a dye laser, or a frequency doubled Neodymium, Nd.YAG, Nd:Glass, Nd:YLF,
  • the second laser may be a dye laser or a solid
  • 3 state laser including a ruby, Ti: Sapphire, SM :YLF or any chromium laser in assorted host materials KZnF, , ScBO,,
  • a Model SLL500-M flashlamp-pumped tunable dye laser system supplied by Candela Laser Corporation has been used.
  • the light was delivered through a 1 mm diameter optical fiber cable to a handpiece to illuminate a spot of 1 to 3 mm diameter with a single pulse.
  • the handpiece used was a model number 7040-00-6231 supplied by Candela Laser Corporation.
  • the tunable dye laser was tuned to 504, 590, 694, 720 and 750 nm using a variety of dye mixtures.
  • the laser had a pulse duration of 500 nsec.
  • Energy densities ranging from .25 to 3.0 J/cm 2 at 0.25 J/cm2 increments,
  • pigmentary incontinence (pigment dropping to the dermal layer) was evident. Its severity increased with increased energy density and wavelength. Although pigment was destroyed using all wavelengths, repigmentation occurred more rapidly for the 504 nm irradiation. For the 504 nm irradiation, repigmentation was complete by the thirty-third day after exposure. Repigmentation followed sequentially by order of wavelength, with the 750 nm irradiated skin taking up to six weeks for its pigment to return to normal.
  • the superficial lesions have been exposed to 504 nm laser irradiation. Pulse durations of 250 nsec, 500 nsec and 1 ⁇ sec have been used with fluence
  • a 3 mm diameter spotsize was used with the 500 nsec and 1 ⁇ sec pulse durations. Because of limits in energy available from the particular laser used, a 2 mm diameter spotsize was used with 250 nsec pulse durations. A 1 mm diameter spotsize was used in limited tests of 6 to 8
  • wavelengths of less than 345 nm should not be used. It is postulated that the shorter wavelengths are most effective with least damage because they are absorbed by blood in the dermis and thus create thermal effects which minimize pigmentary incontinence.
  • the depth of penetration in Caucasian skin which is inversely related to absorption, for 350 nm, 500 nm, 600 nm and 700 nm is about 60 ⁇ , 230 ⁇ , 550 ⁇ and 750 ⁇ , respectively.
  • 2 nm is about 0.5 to 1.0 J/cm for 345 nm, and 5 to 10
  • the first laser configured to provide a beam having these parameters may be employed to effectively treat epidermal pigmentation abnormalities.
  • treatment of pigmentation abnormalities in the dermis are also of interest, and longer wavelengths have been shown to be more effective due to greater depths of penetration.
  • Tattoo treatment with a Q-switched ruby laser was studied by clinical assessment as presented in Taylor et al., "Treatment of
  • a problem encountered with laser treatment using longer wavelength beams is that of pigmentary incontinence where pigment from the epidermis is driven to the lower dermis.
  • One means of treating the deeper lesions with longer wavelengths without pigmentary incontinence is to remove the pigment in the epidermis using the shorter wavelengths and subsequently treat the lower regions with longer wavelengths before normal epidermal pigment returns.
  • the shorter wavelengths remove the pigment from the epidermis to create a window through which the light can pass into the dermis. Without pigment in the epidermis, illumination using the longer wavelengths cannot cause the pigmentary incontinence .
  • Effective treatment with minimal damage should be achieved with the second laser having a wavelength of about 750 nm, a pulse duration of about 100 nsec and a
  • the 2 may provide a fluence ranging from 1 to 10 J/cm at the skin through a range of wavelengths between 600 and 1100 nm. The longer wavelengths are optimal to achieve the depths of penetration associated with deeper pigmentation abnormalities including pigmented lesions and tattoos.
  • the present invention comprises a pair of lasers each providing a pulsed beam of laser radiation having specific parameters for obtaining effective treatment of epidermal and dermal pigmentation abnormalities while minimizing damage to normal pigmented cells.
  • Effective treatment of epidermal pigmentation abnormalities may be achieved by employing a first beam having a wavelength between 345 and 600 nm, a pulse duration of less than 1 ⁇ sec, and a fluence between
  • effective treatment of dermal pigmentation abnormalities may be achieved by employing a second beam having a wavelength between 600 and 1100 nm, a pulse duration of less than
  • such treatment is administered by delivering laser radiation from the lasers to the skin with a delivery system.
  • a flexible solid core single optical fiber is generally one of the most convenient delivery means for delivering a beam of laser radiation to illuminate a pigmented region of skin.
  • a solid core fiber smaller than about 1 mm in diameter would be required because a larger fiber is too rigid.
  • the maximum power density a 1 mm solid fiber can transmit is about 5 MW/mm 2. Since peak laser beam intensities in the present invention may be up to ten times the maximum power density of the fiber (i.e. up to about 46 MW/mm 2), the fiber will be damaged or destroyed.
  • a large diameter fiber would be required to handle the peak intensities, but such a fiber would be inflexible.
  • solid core single optical fibers are not suitable delivery systems for the dual laser system.
  • the present invention employs a delivery system capable of transmitting high peak intensity pulses of wavelength between 345 and 1100 nm with minimal loss and which is flexible for convenience of use.
  • the delivery system 13 comprises a pair of liquid core light guides 14 and 15 for delivery of laser radiation in dermatology procedures.
  • the light guides are flexible and have a sufficient core diameter to transmit high peak intensity pulses of laser radiation with low losses.
  • the first liquid core light guide 14 delivers the first beam of laser radiation of wavelength 2 between 345 and 600 nm, fluence of 1 to 10 J/cm at the skin and pulse duration of less than 1 ⁇ sec to the handpiece 16 for treatment of epidermal pigmentation abnormalities.
  • the second liquid core light guide 15 delivers the second beam of laser radiation of wavelength
  • the guide has a liquid core 42 comprising a liquid 43 which allows the transmission of light having a wavelength between 345 and 600 nm through the guide.
  • the liquid core is housed in a flexible, thermostable, plastic cladding 44.
  • the cladding has a lower refractive index than the liquid, producing total internal reflection at the core/clad interface such that light may be transmitted around Trends in the light guide.
  • the flexible guide transmits light independent of its configuration.
  • the guide has an core diameter in the range of 3 to 10 mm and preferrably about 3 mm such that the guide is capable of transmitting high peak power density pulses of laser radiation.
  • a metallic monocoil tube 46 surrounding the cladding has tooth-like contour which facilitates flexibility.
  • a pair of end pieces 50 fasten around the windows and secure the cladding and the monocoil tube.
  • An outer sleeve 48 encloses the monocoil tube and provides outer mechanical protection.
  • a flexible liquid core light guide made by Lumatec Gmbh, having an aqueous inorganic salt solution within the liquid core, performs well in the spectral region from about 400 to 600 nm. 5 More specifically, the light guide 14 (made by Lumatec) has been used with a laser which produces 2 J, 300 nsec,
  • the 5 second liquid core light guide must employ a liquid having no chemical bonds involving hydrogen or any other bonds which lead to absorption in the range of 600 to 1100 nm. Further, it has been determined that the liquid must satisfy other criteria relating to its physical Q properties including low volatility, low gain coefficients for stimulated scattering and acceptable index of refraction as explained below.
  • Two classes of chemical compounds having no chemical bonds that lead to the aforementioned absorption are completely deuterated compounds and halogenated compounds, specifically halocarbons .
  • the selected compound must be a liquid so that the guide remains flexible. Additionally, the compound must have low gain coefficients which provide an indication of the likelihood of stimulated scattering processes (Brillouin and Raman scattering) for a given laser peak power density. The gain coefficients must be sufficiently low such that the peak power density to be transmitted is below the critical intensity for the threshold of these non-linear scattering effects. Furthermore, the refractive index of the liquid must be greater than the refractive index of the cladding for the guide to transmit radiation with minimal losses. If an otherwise suitable liquid comprising a deuterated compound such as deuterium oxide has an unacceptably low index of refraction, a solute such as an inorganic salt may be added to increase its index to an acceptable value .
  • a light guide comprising the halocarbon carbon tetrachloride has been tested as the core liquid.
  • the light guide cladding material had an index of refraction of about 1.4 and the core liquid had an index of refraction of about 1.5.
  • Alexandrite laser pulses at a wavelength of 760 nm, energy of 1 J and 55 ns pulse duration were successfully transmitted at 80% over 1.5 meters in guide having a 5 mm diameter core.
  • the output spectrum from the guide was observed and showed no evidence of wavelength shifts produced by stimulated scattering.
  • the halocarbon tetrachloroethylene has been tested with alexandrite laser pulses up to 600 mJ and demonstrates the same percentage transmission.
  • the delivery system 13 comprises a single liquid core light guide 15 for efficiently transmitting high peak power intensity pulses of wavelengths between 345 and 1100 nm from the dual laser system.
  • the light guide 15 comprises a liquid 43 capable of transmitting laser radiation in the wavelength range of the first laser as well as the second laser.
  • the light guide 15 is coupled to both lasers via an optical coupler 38 and delivers radiation provided by the first laser for treatment of epidermal pigmentation abnormalities and radiation provided by the second laser for treatment of dermal pigmentation abnormalities.
  • the liquid within the second light guide may comprise silicate compounds or nitrile compounds.

Abstract

An apparatus comprises a first pulsed laser producing a beam of laser radiation having a wavelength between 345 and 600 nm for the treatment of epidermal pigmented lesions and a second pulsed laser producing a beam of laser radiation having a wavelength between 600 and 1100 nm for the treatment of dermal pigmented lesions. A delivery system is coupled to the apparatus and manipulated to deliver radiation to illuminate an area of a subject's skin. The delivery system of the present invention comprises a pair of flexible liquid core light guides having sufficient diameter to efficiently transmit high peak power intensity pulses of wavelengths between 345 and 1100 nm. For treatment of epidermal pigmented lesions, a first liquid core light guide delivers laser radiation of between 345 and 600 nm and preferably about 500 nm wavelength. The fluence is between 1 and 10 J/cm2 at the skin and preferably between 2 and 4 J/cm2. The pulse duration is less than 1 νsec and preferably less than 500 nsec. A 2 to 5 mm diameter spot is illuminated. For treatment of dermal pigmented lesions such as tattoos, a second liquid core light guide delivers laser radiation of between 600 and 1100 nm, fluence is between 1 and 10 J/cm2 at the skin, pulse duration is less than 500. Once again, a 2 to 5 mm diameter spot is illuminated.

Description

APPARATUS_FOR_TREATING_ABNORMAL PIGMENTATION OF THE SKIN
---;£--:--i££H-2-5_£-l_-i-2£_-∑-X£S-t-£--:
Abnormal pigmentation of the skin is commonly seen in der atologic practice. A subject's skin may have pigmentation abnormalities due to vascular lesions, naturally occuring pigmented lesions, or tattoos. Vascular lesions such as port wine stain birthmarks, telangiectasia and hemangiomas are caused by the abundance of enlarged blood vessels. Pigmented lesions are non-vascular disfigurements of the skin caused by an abnormally high concentration of melanin in localized areas of the skin. Such pigmented lesions include freckles, age or liver spots, cafe' au lait birthmarks, lentigines , nevi , melanomes , nevus of Ota and lentigo maligna. Tattoos may be divided into two categories, including self-inflicted or traumatic tattoos. Traumatic tattoos are created during accidents which cause a scrape or abrasion such that a foreign material becomes imbedded in the skin.
A myriad of therapeutic modalities including liquid nitrogen, electrocautery and depigmenting chemicals have been used to remove superficial pigmented lesions. Although widely used, none have succeeded in destroying the abnormal pigmented cells alone without damaging adjacent structures and producing adverse effects like hypopigmentatio .
Over the last two decades , there have been several reports describing the removal of superficial pigmented lesions by a variety of lasers such as the excimer (351 nm) , argon (488,514 nm) , ruby (694 n ) , Nd:YAG (1060 nm) , and CO- (10,600 nm) lasers. However, there has generally been damage to both pigmented and nonpig ented cells. Pigmented lesions treated by laser have included *-> lentigines, nevi, melanomas, oral hypermelanosis of
Peutz-Jeghers syndrome, the nevus of Ota, and a lentigo maligna. The pigment depth of these laser- reated lesions has also varied significantly, from superficial lentigines in the epidermis to lesions lying deep in the 0 reticular dermis like the nevus of Ota.
Previous studies reporting "successful" removal of pigmented lesions have relied on clinical assessment rather than on histology and have used widely divergent wavelengths, pulse durations, energy densities and 5 spotsizes. There has been no effort to define laser parameters necessary for optimal removal of pigmented lesions .
Melanin, an endogenous cutaneous pigment which is most concentrated in the basal layer of the epidermis, 0 has an absorption spectrum that is highest in the ultraviolet range and gradually diminishes toward the infrared. Melanosomes are melanocyte-specific organelles densely packed with melanin. They vary in size according to their genetic origin; black skin typically containing 5 larger melanosomes than lightly pigmented, white skin. Based on melanosome size, the calculated thermal relaxation time for these organelles is around 10 nsec. On the other hand, melanocytes are approximately 7 μm in diameter, with thermal relaxation times around 1 μsec. 0 Thermal relaxation time in both instances is defined as the time taken for a structure to cool to 50% of its peak temperature immediately after laser exposure. Recent studies have applied the technique of selective photothermolysis to specifically destroy melanosomes using the XeF pulsed excimer is_vi.tro and the Q-switched ruby lasers iB_Y- £- Histologicall , both these studies demonstrated melanosomal injury that was associated with disruption of melanocytes as well as melanin-containing basal keratinocytes . In addition, there was also evidence of follicular damage after exposure of pigmented guinea pig skin to the Q-switched ruby laser.
Selective photothermolysis has also been employed in other studies to treat tattoos. It was demonstrated that a Q-switched ruby laser is not effective for all types of tattoos, because tattoos are often multicolored. These studies have shown that blue-black tattoos responded well to Q-switched ruby laser treatment, while green .and yellow tattoos responded less than well and red tattoos responded poorly or not at all. Additionally, persistent hypopigmentation was a frequent occurrence.
Di.s_£l1 s_ur^_£f_^he_I_nven^£n
In accordance with the present invention, an apparatus produces a plurality of pulsed beams of laser radiation for the treatment of epidermal and dermal pigmentation abnormalities of the skin. By having the capability to provide plural laser beams of different wavelengths (colors), the range of applications for which the apparatus is effective increases significantly. An apparatus capable of providing one of two beams of different wavelengths is believed to be sufficiently effective for the majority of cases in therapeutic dermatology and plastic surgery involving treatment of non-vascular pigmentation abnormalities. The apparatus comprises a first pulsed laser producing a first beam principally for the treatment of epidermal pigmentation abnormalities and a second pulsed laser producing a second beam principally for the treatment of dermal pigmentation abnormalities. In one embodiment, the first laser is pulsed dye laser supported by a dye circulation system and the second laser is an alexandrite laser. The two lasers are coupled to a common power supply and storage system. The lasers are excited by a flashlamp means which may comprise a single coaxial flashlamp for exciting both lasers or a pair of coaxial flashlamps for separately exciting each laser. In another embodiment, the first laser is used to excite the second laser in a laser excited configuration. In this embodiment, the first laser is preferrably a flashlamp excited pulsed dye laser and the second laser is preferrably an alexandrite laser.
In accordance with one feature of the present invention, specific laser parameters are established to obtain effective treatment of epidermal and dermal pigmentation abnormalities while minimizing damage to normal pigmented cells. To that end, effective treatment of epidermal lesions with minimal damage has been obtained with a first laser having a wavelength of about 500 nm, a pulse duration of about 500 nsec, and fluence
2 (energy density) of about 3 J/cm at the skin. The spotsize may range from about 2 to 5 mm diameter, but preferrably it is about 3 mm diameter. To minimize damage, wavelength of the first beam should be less than 600 nm. Due to known problems of mutagenesis, the wavelength should not be less than 345 nm. The fluence
2 of the first beam may range from 1 to 10 J/cm at the skin through the full range of wavelengths , but is 2 preferably within the range of 2 to 4 J/cm for 504 nm light. Pulse durations approaching 1 /-sec may be used but at 1 /-sec recurrence is expected. Shorter pulse durations should minimize damage to normal tissue.
To avoid pigmentary incontinence of the epidermal pigment resulting from laser irradiation and to get better access to dermal pigment to effectively treat dermal pigmentation abnormalities, a window is created in the epidermis using the above defined laser parameters and the deeper cells are treated with the second laser having parameters specific to those cells. More specifically, it is expected that effective treatment with minimal damage may be obtained with the second laser having a wavelength of about 750 nm, a pulse duration of
2 about 100 nsec and an energy of about 1 J/cm at the skin. The fluence at the skin for the second beam may
2 range from 1 to 10 J/cm through a range of wavelengths between 600 and 1100 nm, but it is preferrably within the
2 range of 1 to 4 J/cm for 760 nm light. The spotsize may range from about 2 to 5 mm diameter, but preferrably it is about 3 mm diameter. The longer wavelengths are required to penetrate to depths associated with the location of dermal pigmentation abnormalities.
In a typical dermatology procedure, treatment is adminstered with a delivery system which is manipulated to deliver radiation to illuminate an area of a subject's skin. For effective treatment, the dual laser system requires pulse durations on the order of tens to hundreds of nanoseconds for potentially high intensity pulses. Thus, the delivery system must be capable of transmitting high peak intensity pulses with low losses and must be flexible for convenience of use. 6 -
To that end, one embodiment of the preferred delivery system of the present invention comprises a pair of flexible liquid core light guides having sufficient diameter to efficiently transmit high peak power intensity pulses of wavelengths between 345 and 1100 nm from the dual laser system. More specifically, a first liquid core light guide delivers the first beam of laser radiation of wavelength between 345 and 600 nm, fluence
2 of 1 to 10 J/cm at the skin and pulse duration of less than 1 μsec to the handpiece for treatment of epidermal pigmented lesions. The first liquid core light guide has a liquid core comprising an aqueous inorganic salt solution within a flexible cladding which facilitates the transmission of laser radiation of wavelengths between 345 and 600 nm. The core diameter may be between 3 and 10 mm and preferrably about 3 mm such that the first guide is capable of transmitting high peak intensity pulses. However, the liquid within the first guide does not effectively transmit radiation of wavelengths between 600 and 1100 nm due to the presence of chemical bonds involving hydrogen which significantly attenuate the radiation.
The second liquid core light guide delivers the second beam of laser radiation of wavelength between 600
2 and 1100 nm, fluence of 1 to 10 J/cm at the skin and pulse duration of less than 500 nsec to the handpiece for treatment of dermal pigmentation abnormalities such as tattoos. The second guide has a liquid core comprising a liquid and housed within a flexible cladding. The liquid has a molecular structure characterized by the absence of chemical bonds which would cause absorption between wavelengths 600 and 1100 nm. As a minimum, the liquid is non-hydrogenous and comprises halogenated compounds. Preferrably, the liquid comprises halocarbons such as tetrachloroethylene or carbon tetrachloride , or a solution of inorganic salts in deuterium oxide. The index of refraction for the liquid is greater than the index of refraction for the cladding. The liquid core of the second light guide has a diameter between 3 and 10 mm and preferrably about 5 mm such that the second guide is capable of transmitting high peak intensity pulses.
Another embodiment of the preferred delivery system of the present invention comprises a flexible liquid core light guide for efficiently transmitting high peak power intensity pulses of wavelengths between 345 and 1100 nm from the dual laser system. More specifically, the second light guide comprises a liquid capable of delivering laser radiation from the first laser for treatment of epidermal pigmentation abnormalities and from the second laser for treatment of dermal pigmentation abnormalities. In this embodiment, the light guide is coupled to both lasers and delivers radiation from the particular laser being employed for treatment.
Other advantages and features of the invention will become apparent from the following description of the preferred embodiments, and from the claims.
Bri f_De £rΪ£ti.£n_£f_the__Drawi^ g
Fig. 1 illustrates a dual laser system with separate delivery systems.
Fig. 2 is an enlarged perspective view of the handpiece of Fig. 1. Fig. 3 is a block diagram of a preferred embodiment dual laser system. Fig. 4 is a block diagram of another preferred embodiment dual laser system.
Fig. 5 is a block diamgram of yet another preferred embodiment dual laser system. Fig. 6 is a cross-sectional view of a liquid core light guide of Fig. 1.
Description of Preferred_Embodiments
Pigmentation abnormalities may be removed from the skin by lasers provided that the lasers have the proper characteristics based on the principles of selective photothermolysis. These principles require the proper selection of wavelength (or color) of the laser to maximize absorption within the targeted lesion and minimize absorption by the surrounding normal tissue, organs or organelles. Selective photothermolysis also requires the precise selection of pulse duration of the laser beam which is determined by the thermal relaxation time of the target. Pulse duration should be shorter than the thermal relaxation so that only the targeted material is heated and the surrounding tissue is unaffected.
Pigmented lesions have broad band absorption characteristics with high absorption at shorter wavelengths (blue-violet) arid decreasing monotonically to higher wavelengths (red). Additionally, it has been shown that shorter wavelength (blue-green) lasers treat superficial pigmented lesions better than longer wavelength (red) lasers. On the other hand, longer wavelength (red) lasers are more effective for treating dermal pigmentation abnormalities including deeper pigmented lesions and tattoos. However, it has been demonstrated that the long wavelength ruby red laser is 9 -
not effective for tattoos. Blue and black tattoos respond well to ruby laser treatment, while green and yellow tattoos respond less well and red tattoos respond poorly. These results are predicable based on the 5 absorption characteristics of the tattoo pigments. It is therefore desirable to tailor the wavelength (color) of the laser radiation to the absorption characteristic of the targeted material within the skin.
In accordance with the present invention, a laser
10 system 12 provides two pulsed beams of laser radiation having distinct wavelengths which may be employed for the treatment of epidermal and dermal pigmented lesions of the skin (see Fig. 1). Although a laser system producing more than two different wavelength beams is within the
15 scope of this invention, discussion is limited to a laser system providing two different wavelength pulsed beams. Also, the specific parameters of each laser beam including wavelength, intensity and pulse duration are discussed in detail below.
20 A delivery system 13 is coupled to the laser system 12 and delivers the two laser beams to a pigmented region of the skin. In a preferred embodiment, the first laser beam is delivered through a first light guide 14 to a handpiece 16 and second laser beam is delivered through a
25 second light guide 15 to a handpiece 17. In another preferred embodiment, the delivery system may comprise only the second light guide 15 and the handpiece 17 (Fig. 5). In this embodiment, both laser beams are coupled to the guide 15 which delivers either beam to the skin for
30 treatment of pigmentation abnormalities. Alternatively, one or both laser beams may be delivered through an articulated arm (not shown) . The features of the first and second light guides are discussed in detail below. A preferred handpiece, illustrated in Fig. 2, is model number 7040-00-6231 sold by Candela Laser Corporation. Two lenses in the handpiece image the distal end of the guide to a larger spot adjacent to the end of a positioning extension 18. By selection of the lenses, the spotsize can be varied. The spotsize may be between 2 and 5 mm diameter and is preferrably about 3 mm diameter. By movement of the handpiece and irradiation of adjacent spots, a test site of a1-*out 0.5-1.0 cm x 0.5-1.0 cm may be irradiated at a selected dose.
In a preferred embodiment of the laser system, as shown in Fig. 3, the laser system 12 comprises a pair of laser systems 20 and 22. The laser systems comprise a pair of flashlamp excited pulsed lasers 21 and 23 having a common power supply/storage system 24. The lasers are excited by a flashlamp means which may comprise a single coaxial flashlamp (not shown) or a pair of coaxial flashlamps 26 and 27 for separately exciting the first and second laser 21 and 23 respectively. Preferrably, the first laser 21 is a pulsed dye laser having a dye circulation system 28 and the second laser 23 is an alexandrite laser. Alternatively, both lasers may be pulsed dye lasers with separate circulation systems. Furthermore, one or both of the laser systems 20 and 22 may comprise any non-dye pulsed laser system such as a solid state laser.
In another preferred embodiment, shown in Fig. 4, a first laser system 20 is arranged to excite a second laser system 22 in a laser-excited configuration. Preferrably, the first laser 20 is a flashlamp excited pulsed dye laser supported by a dye circulation system 28 and the second laser 32 is an alexandrite laser. In yet another preferred embodiment, shown in Fig. 5, the pair of laser systems 20 and 22 are coupled by an optical coupler 38 to the delivery system 13 comprising a single light guide 17. In any of the preferred embodiments, the laser systems 20 and 22 may comprise any combination of the following lasers to provide a short wavelength beam and a long wavelength beam of laser radiation.
Accordingly, the first laser may be a dye laser, or a frequency doubled Neodymium, Nd.YAG, Nd:Glass, Nd:YLF,
Ti : Sapphire , frequency doubled Alexandrite or excimer laser. The second laser may be a dye laser or a solid
3 state laser including a ruby, Ti: Sapphire, SM :YLF or any chromium laser in assorted host materials KZnF, , ScBO,,
LaLuGG, GSGG, YSGG, YGG , BeAL- (SO.),.
Specific laser parameters have been established for the dual laser system to obtain effective treatment of epidermal and dermal pigmented lesions while minimizing damage to normal pigmented cells and are hereinafter discussed.
A wide range of experimental treatments have been performed on the normally pigmented skin of miniature black pigs and those have been followed by extensive clinical studies. A first set of experiments was performed to identify shorter wavelengths in the green portion of the spectrum for the minimization of epidermal damage, particularly pigmentary incontinence, as well as regeneration of normal pigment cells. A second set of experiments using the optimum laser wavelength of 504 nm has identified shorter pulse durations as preferred for minimizing epidermal damage. Finally, clinical studies of human patients have demonstrated that laser light of the shorter wavelengths and shorter pulse durations is most effective in treating the epidermal pigmented lesions with treatment fluences at the skin of about 3 12
2 J/cm . Limited human pigmented lesion studies have demonstrated lack of ef ectiveness in treating epidermal pigmented lesions at 694 nm and 750 nm.
In the experiments related to epidermal (superficial) pigmented lesions, a Model SLL500-M flashlamp-pumped tunable dye laser system supplied by Candela Laser Corporation has been used. The light was delivered through a 1 mm diameter optical fiber cable to a handpiece to illuminate a spot of 1 to 3 mm diameter with a single pulse. The handpiece used was a model number 7040-00-6231 supplied by Candela Laser Corporation.
In the first set of experiments on normal black pig skin, the tunable dye laser was tuned to 504, 590, 694, 720 and 750 nm using a variety of dye mixtures. The laser had a pulse duration of 500 nsec. Energy densities ranging from .25 to 3.0 J/cm 2 at 0.25 J/cm2 increments,
2 and at 4.0, 5.0, 6.0 and 7.0 J/cm were delivered to pigmented skin at a spotsize of 3 mm diameter. The skin was irradiated at each energy density for each of the five wavelengths tested. Skin biopsies were taken at each energy density from each of the five wavelengths immediately and at 4, 16, 23 and 33 days after laser exposure. These experiments were published by Sherwood et al. , "Effect of wavelength on cutaneous pigment using pulsed irradiation," The Journal of Investigative
Dermatology, Vol. 92, No. 5, May 1989.
Exposure of skin to energy densities of at least 5
2 2
J/c for 590 and 694 nm and 4.0 J/cm for 720 and 750 nm resulted in sub-epidermal clefts accompanied by epidermal necrosis. No sub-epidermal clefts or epidermal necrosis were observed after exposure of skin to 504 nm irradiation, not even at the highest energy density of 2 7.0 J/cm . In addition to epidermal injury, dermal damage consisting of collagen bundle separation accompanied by changes in the tinctorial quality of the bundles were observed in biopsies taken from the skin
2 exposed to 7.0 J/cm at the four wavelengths other than
504 nm. The extent of dermal injury appeared dependent on the wavelength; the most severe occurring at 750 nm.
From biopsies, pigmentary incontinence (pigment dropping to the dermal layer) was evident. Its severity increased with increased energy density and wavelength. Although pigment was destroyed using all wavelengths, repigmentation occurred more rapidly for the 504 nm irradiation. For the 504 nm irradiation, repigmentation was complete by the thirty-third day after exposure. Repigmentation followed sequentially by order of wavelength, with the 750 nm irradiated skin taking up to six weeks for its pigment to return to normal.
In the second set of experiments, miniature black pig skin was again irradiated. Using a 504 nm laser and 3 mm diameter spotsize, the effect of pulse durations of
100, 150, 250 and 500 nsec at fluences from 1.5 to 4.0
2 2
J/cm , at 0.5 J/cm increments, were examined. Biopsies were taken immediately and at 7 , 14 and 28 days after irradiation and were processed for light microscopy. The most severe damage was observed in skin exposed to pulse durations of 250 and 500 nsec. Epidermal necrosis, dermal-epidermal separation and pigmentary incontinence were not only more severe, but also occurred at significantly lower fluences than was evident in skin exposed to 100 and 150 nsec pulse durations. Although the normal cells repigment, the unsightly damage remains.
In the final clinical studies with human patients, superficial benign cutaneous pigmented lesions had been treated by using the pulse irradiation. Fifty-two patients have been treated variously for the following: lentigines, solar keratoses/' lentignes ' , cafe' au lait, seborrheic keratoses, hyperpigmentation associated with morphoea, nevus spilus.
Generally, the superficial lesions have been exposed to 504 nm laser irradiation. Pulse durations of 250 nsec, 500 nsec and 1 μsec have been used with fluence
2 ranging from 1.5 to 3.5 J/cm for each pulse duration. A 3 mm diameter spotsize was used with the 500 nsec and 1 μsec pulse durations. Because of limits in energy available from the particular laser used, a 2 mm diameter spotsize was used with 250 nsec pulse durations. A 1 mm diameter spotsize was used in limited tests of 6 to 8
2 J/cm , but excessive dermal damage was noted. This is consistent with findings presented in Tan et al. ,
"Spotsize effects on guinea pig skin following pulsed irradiation, " The Journal of Inyestiga.tiye Derma.tolo ,
Vol. 90, No. 6, June 1988. At all pulse durations,
2 2 incomplete lightening was found at 2 J/cm and 2.5 /cm .
2 The 3.0 J/cm was found to be the most effective dose.
2 The 3.5 J/cm was only used in a limited number of tests
2 where insufficient response was obtained at 3.0 J/cm and was effective. With the 1 μsec pulse duration, the lesions cleared but recurred. At 500 nsec, nonrecurring clearance was obtained. At 250 nsec, clearance was also obtained, and we are awaiting final results. Clinical observations indicate minimal dermal damage without noticeable pigmentary incontinence.
2 With limited tests at 504 nm and 4 J/cm , some permanent loss of normal pigment and undesirable surface changes were noted. However, with appropriate selection of other parameters, higher fluences may be feasible. Limited tests of a 694 nm Q-switched ruby laser
2 having a pulse duration of 20 nsec and fluence of 5 J/cm proved ineffective in removing the superficial lesions.
Similarly, a Q-switched alexandrite laser of 760 n , 100
2 nsec and 3 J/cm was ineffective in treating the superficial lesion with a 2mm spotsize.
Limited tests at 577 nm, 360 nsec resulted in clearance of the lesion but with recurrence. However, lesions are expected to be effectively treated with that wavelength at shorter pulse durations. To minimize adverse effects, particularly due to pigmentary incontinence, wavelengths of about 600 n or less are judged best from the first set of experiments.
Although 504 nm is the shortest wavelength tested, it is the most effective, and it is expected that shorter wavelengths within the melanin absorption spectrum will provide desirable results. Due to concerns for mutagenesis, wavelengths of less than 345 nm should not be used. It is postulated that the shorter wavelengths are most effective with least damage because they are absorbed by blood in the dermis and thus create thermal effects which minimize pigmentary incontinence.
It is expected that the acceptable fluence range at the skin is a function of wavelengths. At 504 nm, some
2 effect on melanin is noted at 2 J/cm , and damage is seen
2 above 4 J/cm . The depth of penetration in Caucasian skin, which is inversely related to absorption, for 350 nm, 500 nm, 600 nm and 700 nm is about 60 μ, 230 μ, 550 μ and 750 μ, respectively. Thus, expected ranges of effect
2 without damage, based on the 2 to 4 J/cm range at 504
2 nm, is about 0.5 to 1.0 J/cm for 345 nm, and 5 to 10
2 J/cm for 600 nm. In general, it is expected that
2 fluences of 1 to 10 J/cm at the skin will be used for wavelengths of 345 nm to 600 nm. Thus, the first laser configured to provide a beam having these parameters may be employed to effectively treat epidermal pigmentation abnormalities. On the other hand, treatment of pigmentation abnormalities in the dermis are also of interest, and longer wavelengths have been shown to be more effective due to greater depths of penetration. Tattoo treatment with a Q-switched ruby laser was studied by clinical assessment as presented in Taylor et al., "Treatment of
Tattoos by Q-Switched Ruby Laser," Ar£h_. Derma££l£gy, Vol
126, July 1990. The tattoos were exposed to 694 nm laser irradiation. Pulse durations of 40 to 80 nsec with
2 fluence ranging from 1.5 to 8 J/cm for each pulse duration. All tattoos contained blue-black pigment and a few also had small areas of red, yellow, or green. It was demonstrated that the blue-black tattoos responded well to ruby laser treatment. However, the green and yellow areas responded less than well and the red areas responded poorly or not at all.
A problem encountered with laser treatment using longer wavelength beams is that of pigmentary incontinence where pigment from the epidermis is driven to the lower dermis. One means of treating the deeper lesions with longer wavelengths without pigmentary incontinence is to remove the pigment in the epidermis using the shorter wavelengths and subsequently treat the lower regions with longer wavelengths before normal epidermal pigment returns. Thus, the shorter wavelengths remove the pigment from the epidermis to create a window through which the light can pass into the dermis. Without pigment in the epidermis, illumination using the longer wavelengths cannot cause the pigmentary incontinence .
Effective treatment with minimal damage should be achieved with the second laser having a wavelength of about 750 nm, a pulse duration of about 100 nsec and a
2 fluence of about 1 J/cm at the skin. The second beam
2 may provide a fluence ranging from 1 to 10 J/cm at the skin through a range of wavelengths between 600 and 1100 nm. The longer wavelengths are optimal to achieve the depths of penetration associated with deeper pigmentation abnormalities including pigmented lesions and tattoos.
Based on the aforementioned tests, the present invention comprises a pair of lasers each providing a pulsed beam of laser radiation having specific parameters for obtaining effective treatment of epidermal and dermal pigmentation abnormalities while minimizing damage to normal pigmented cells. Effective treatment of epidermal pigmentation abnormalities may be achieved by employing a first beam having a wavelength between 345 and 600 nm, a pulse duration of less than 1 μsec, and a fluence between
2 1 and 10 J/cm at the skin. Additionally, effective treatment of dermal pigmentation abnormalities may be achieved by employing a second beam having a wavelength between 600 and 1100 nm, a pulse duration of less than
2 500 nsec and a fluence between 1 and 10 J/cm at the skin. In a typical dermatology procedure, such treatment is administered by delivering laser radiation from the lasers to the skin with a delivery system.
Because the present invention requires pulse durations on the order of tens of nanoseconds to hundreds of nanoseconds and potentially high power densities, the delivery system must be capable of transmitting high peak intensity pulses with minimal losses and must be flexible for convenience of use. An articulated arm multiple mirror system has been used for high peak power applications in a dermatology procedure and may be employed. However, an articulated arm is bulky, cumbersome and difficult to align. Multifiber bundle cables are not appropriate because of high transmission losses related to the core/clad ratio. A flexible solid core single optical fiber is generally one of the most convenient delivery means for delivering a beam of laser radiation to illuminate a pigmented region of skin. A solid core fiber smaller than about 1 mm in diameter would be required because a larger fiber is too rigid.
However, the maximum power density a 1 mm solid fiber can transmit is about 5 MW/mm 2. Since peak laser beam intensities in the present invention may be up to ten times the maximum power density of the fiber (i.e. up to about 46 MW/mm 2), the fiber will be damaged or destroyed.
A large diameter fiber would be required to handle the peak intensities, but such a fiber would be inflexible. Thus, solid core single optical fibers are not suitable delivery systems for the dual laser system.
The present invention employs a delivery system capable of transmitting high peak intensity pulses of wavelength between 345 and 1100 nm with minimal loss and which is flexible for convenience of use. In one preferred embodiment, shown in Fig. 1, the delivery system 13 comprises a pair of liquid core light guides 14 and 15 for delivery of laser radiation in dermatology procedures. The light guides are flexible and have a sufficient core diameter to transmit high peak intensity pulses of laser radiation with low losses. More specifically, the first liquid core light guide 14 delivers the first beam of laser radiation of wavelength 2 between 345 and 600 nm, fluence of 1 to 10 J/cm at the skin and pulse duration of less than 1 μsec to the handpiece 16 for treatment of epidermal pigmentation abnormalities. The second liquid core light guide 15 delivers the second beam of laser radiation of wavelength
2 between 600 and 1100 n , fluence of 1 to 10 J/cm at the skin and pulse duration of less than 500 nsec to the handpiece 17 for treatment of dermal pigmentation abnormalities such as deeper pigmented lesions and tattoos .
A cross-sectional view of a liquid core light guide 40 is presented in Fig. 6. In one embodiment, the guide has a liquid core 42 comprising a liquid 43 which allows the transmission of light having a wavelength between 345 and 600 nm through the guide. The liquid core is housed in a flexible, thermostable, plastic cladding 44. The cladding has a lower refractive index than the liquid, producing total internal reflection at the core/clad interface such that light may be transmitted around Trends in the light guide. Thus, the flexible guide transmits light independent of its configuration. The guide has an core diameter in the range of 3 to 10 mm and preferrably about 3 mm such that the guide is capable of transmitting high peak power density pulses of laser radiation. These laser pulses enter and exit the guide 40 at a pair of silica rod windows 45 which also seal liquid with the guide. A metallic monocoil tube 46 surrounding the cladding has tooth-like contour which facilitates flexibility. A pair of end pieces 50 fasten around the windows and secure the cladding and the monocoil tube. An outer sleeve 48 encloses the monocoil tube and provides outer mechanical protection. Experiments have shown that a flexible liquid core light guide, made by Lumatec Gmbh, having an aqueous inorganic salt solution within the liquid core, performs well in the spectral region from about 400 to 600 nm. 5 More specifically, the light guide 14 (made by Lumatec) has been used with a laser which produces 2 J, 300 nsec,
2 1 to 10 J/cm pulses at a wavelength of 510 nm to effectively treat epidermal pigmented lesions.
Although the first liquid core light guide 14 has
10 been shown to effectively deliver pulsed laser radiation in the spectral range from about 400 to 600 nm, it does not effectively transmit laser radiation of wavelengths between 600 and 1100 nm (red and near infrared wavelengths) . The poor transmission capability of the l~ liquid of the first guide in the red and near infrared spectral range is due to the presence of chemical bonds involving hydrogen in the molecular structure of the liquid in the core. Overtone and combination bands of fundamental frequencies associated with such bonds lead
20 to absorption coefficients which are large enough to significantly attenuate the beam of pulsed laser radiation over distances required for convenient delivery (approximately 1.5 meters). Thus, to effectively transmit laser radiation from the second laser, the 5 second liquid core light guide must employ a liquid having no chemical bonds involving hydrogen or any other bonds which lead to absorption in the range of 600 to 1100 nm. Further, it has been determined that the liquid must satisfy other criteria relating to its physical Q properties including low volatility, low gain coefficients for stimulated scattering and acceptable index of refraction as explained below. Two classes of chemical compounds having no chemical bonds that lead to the aforementioned absorption are completely deuterated compounds and halogenated compounds, specifically halocarbons . Within these two classes, the selected compound must be a liquid so that the guide remains flexible. Additionally, the compound must have low gain coefficients which provide an indication of the likelihood of stimulated scattering processes (Brillouin and Raman scattering) for a given laser peak power density. The gain coefficients must be sufficiently low such that the peak power density to be transmitted is below the critical intensity for the threshold of these non-linear scattering effects. Furthermore, the refractive index of the liquid must be greater than the refractive index of the cladding for the guide to transmit radiation with minimal losses. If an otherwise suitable liquid comprising a deuterated compound such as deuterium oxide has an unacceptably low index of refraction, a solute such as an inorganic salt may be added to increase its index to an acceptable value .
A light guide comprising the halocarbon carbon tetrachloride has been tested as the core liquid. In accordance with the above-described parameters, the light guide cladding material had an index of refraction of about 1.4 and the core liquid had an index of refraction of about 1.5. Alexandrite laser pulses at a wavelength of 760 nm, energy of 1 J and 55 ns pulse duration were successfully transmitted at 80% over 1.5 meters in guide having a 5 mm diameter core. The output spectrum from the guide was observed and showed no evidence of wavelength shifts produced by stimulated scattering. Additionally, the halocarbon tetrachloroethylene has been tested with alexandrite laser pulses up to 600 mJ and demonstrates the same percentage transmission.
In another preferred embodiment, shown in Fig. 5, the delivery system 13 comprises a single liquid core light guide 15 for efficiently transmitting high peak power intensity pulses of wavelengths between 345 and 1100 nm from the dual laser system. The light guide 15 comprises a liquid 43 capable of transmitting laser radiation in the wavelength range of the first laser as well as the second laser. As such, the light guide 15 is coupled to both lasers via an optical coupler 38 and delivers radiation provided by the first laser for treatment of epidermal pigmentation abnormalities and radiation provided by the second laser for treatment of dermal pigmentation abnormalities.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes In form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims . For example, other classes of chemical compounds having no chemical bonds which lead to absorption within the 600 to 1100 nm range may be used. Thus, the liquid within the second light guide may comprise silicate compounds or nitrile compounds.

Claims

1. An apparatus for treating epidermal and dermal pigmentation abnormalities of the skin comprising: a first pulsed laser for treating epidermal pigmentation abnormalities by providing a first beam of wavelength between 345 and 600 nm, fluence of 1
2 to 10 J/cm at the skin and pulse duration of less than 1 μsec ; a second pulsed laser for treating dermal pigmentation abnormalities by providing a second beam of wavelength between 600 and 1100 nm, fluence
2 of 1 to 10 J/cm at the skin and pulse duration of less than 0.5 nsec; and a delivery system coupled to the first and second lasers for delivery of the first and second laser beams to Illuminate the epidermal and dermal pigmented lesions respectively.
2. An apparatus as claimed in Claim 1 wherein the first laser is a dye laser and the second laser is an alexandrite laser.
3. An apparatus as claimed in Claims 1 wherein the first and second lasers are dye lasers.
4. An apparatus as claimed in Claim 1, 2 or 3 wherein the first laser produces a beam of about 500 nm
2 wavelength, 3 J/cm fluence at the skin, and 500 nsec or less pulse duration.
5. An apparatus as claimed in Claim 1, 2, 3 or 4 wherein the delivery system illuminates a region of about 2 to 5 mm diameter.
6. An apparatus as claimed in Claim 1, 2, 3, or 4 wherein delivery system illuminates a region of about 3 mm diameter.
7. An apparatus as claimed in Claim 1, 2, 3, 4, 5, 6 or 7 wherein the delivery system comprises a flexible liquid core light guide for delivery of the first and second laser beams.
8. An apparatus as claimed in Claim 1, 2, 3, 4, 5, or 6 wherein the delivery system comprises a flexible liquid core light guide for delivery of the second laser beam.
9. An apparatus as claimed in Claim 7 or 8 wherein the liquid core light guide comprises a liquid having a molecular structure characterized by the absence of chemical bonds that cause the absorption of light having wavelengths between 600 and 1100 nm.
10. An apparatus as claimed in Claim 7 or 8 wherein the liquid core light comprises a non-hydrogenous liquid.
11. An apparatus as claimed in Claim 9 or 10 wherein the liquid comprises halogenated compounds.
12. An apparatus as claimed in Claim 9 or 10 wherein the liquid has a molecular structure which comprises halocarbons .
13. An apparatus as claimed in Claim 9 or 10 wherein the liquid comprises tetrachloroethylene .
14. An apparatus as claimed in Claim 9 or wherein the liquid comprises deuterium oxide and inorganic salts .
15. An apparatus as claimed in Claim 9 or 10 wherein the liquid comprises carbon tetrachloride .
16. An apparatus as claimed in Claim 9 or 10 wherein the guide has a core diameter of about 5 mm.
17 An apparatus as claimed in Claim 9, 10, 11, 12, 13, 14, 15 or 16 wherein the liquid core light guide further comprises a flexible, thermostable cladding in which the liquid Is located, wherein the liquid has a refractive index which is greater than the cladding refractive index.
18. An apparatus as claimed in Claim 1, 2, 3, 4, 5, 6 or 7 wherein the delivery system comprises a liquid core light for delivery of the first laser beam and an articulated arm for delivery of the second laser beam.
19. An apparatus as claimed in Claim 8 wherein the delivery system comprises a second flexible liquid core light for delivery of the first laser beam.
20. A dermatology laser apparatus comprising: a pulsed laser for dermatology procedures on a subject's skin by providing a beam of wavelength
2 between 345 and 1100 nm, fluence of 1 to 10 J/cm at
5 the skin and pulse duration of less than 1 μsec; and a flexible liquid core light guide for delivery of the beam to illuminate an area on the subject's skin.
21. An apparatus as claimed in Claim 20 wherein the
10 light guide has a core diameter between 3 and 10 mm.
22. An apparatus as claimed in Claim 20 or 21 wherein the light guide has a core diameter of about 5 mm.
23. An apparatus as claimed in Claim 19, 20, 21 or 22 wherein the light guide further comprises a
15 flexible, thermostable cladding in which a liquid Is located, the liquid having a greater refractive index than the cladding.
24. An apparatus as claimed in Claim 23 wherein the light guide further comprises a pair of windows
^- located at each end of the guide and which seal a liquid within the cladding and a flexible metallic monocoil tube enclosing the cladding.
25. An apparatus as claimed in Claim 19, 20, 21, 22, 23 or 24 wherein the liquid core light guide comprises
25 a non-hydrogenous liquid.
26. An apparatus as claimed in Claim 19, 20, 21, 22, 23 or 24 wherein the liquid core light guide comprises a liquid having a molecular structure characterized by the absence of chemical bonds that cause the absorption of light having wavelengths between 600 and 1100 nm.
27. An apparatus as claimed in Claim 19, 20, 21, 22, 23, 24, 25 or 26 wherein the liquid has a molecular structure which comprises halocarbons.
28. An apparatus as claimed in Claim 19, 20, 21, 22, 23, 24, 25, 26 or 27 wherein the liquid comprises tetrachloroethylene .
29. An apparatus as claimed in Claim 19, 20, 21, 22, 23, 24, 25, 26 or 27 wherein the liquid comprises carbon tetrachloride .
30. An apparatus as claimed in Claim 19, 20, 21, 22, 23, 24, 25 or 26 wherein the liquid comprises deuterated compounds and inorganic salts.
31. A liquid core light guide having a core diameter of about 5 mm and capable of transmitting a beam of laser radiation of a wavelength between 600 and 1100
2 nm and a fluence of at least 1 J/cm , said light guide comprising a liquid having a molecular structure characterized by the absence of chemical bonds that cause the absorption of light having wavelengths between 600 and 1100 nm.
32. An apparatus as claimed in Claim 31 wherein the co.re diameter is between 3 and 10 mm.
33. An apparatus as claimed in Claim 30, 31 or 32 wherein the light guide further comprises a flexible, thermostable cladding in which the liquid is located, the cladding having a refractive index which is less than the refractive index of the liquid.
34. An apparatus as claimed in Claim 30, 31, 32 or 33 wherein the light guide further comprises a pair of windows located at each end of the guide and which seal the liquid within the cladding and a flexible metallic monocoil tube enclosing the cladding.
35. An apparatus as claimed in Claim 30, 31, 32, 33 or 34 wherein the liquid comprises halogenated compounds .
36. An apparatus as claimed in Claim 30, 31, 32, 33, 34 or 35 wherein the liquid has a molecular structure which comprises halocarbons.
37. An apparatus as claimed in Claim 30, 31, 32, 33, 34, 35 or 36 wherein the liquid comprises tetrachloroethylene .
38. An apparatus as claimed in Claim 30, 31, 32, 33, 34, 3? or 36 wherein the liquid comprises carbon tetrachloride .
39. An apparatus as claimed in Claim 30, 31, 32, 33 or
34 wherein the liquid comprises deuterated compounds and inorganic salts.
PCT/US1991/001714 1990-03-14 1991-03-14 Apparatus for treating abnormal pigmentation of the skin WO1991013652A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49330990A 1990-03-14 1990-03-14
US493,309 1990-03-14

Publications (1)

Publication Number Publication Date
WO1991013652A1 true WO1991013652A1 (en) 1991-09-19

Family

ID=23959698

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1991/001715 WO1991013653A1 (en) 1990-03-14 1991-03-14 Apparatus and method of treating pigmented lesions using pulsed irradiation
PCT/US1991/001714 WO1991013652A1 (en) 1990-03-14 1991-03-14 Apparatus for treating abnormal pigmentation of the skin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1991/001715 WO1991013653A1 (en) 1990-03-14 1991-03-14 Apparatus and method of treating pigmented lesions using pulsed irradiation

Country Status (7)

Country Link
US (1) US5312395A (en)
EP (1) EP0519964B1 (en)
JP (1) JPH05505737A (en)
AU (2) AU7463991A (en)
DE (1) DE69103409T2 (en)
IL (1) IL97553A0 (en)
WO (2) WO1991013653A1 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508209A2 (en) * 1991-03-27 1992-10-14 David G. Changaris Method of inducing tanning or DNA repair by pulsed radiation and apparatus to effect same
US5304170A (en) * 1993-03-12 1994-04-19 Green Howard A Method of laser-induced tissue necrosis in carotenoid-containing skin structures
EP0712322A1 (en) * 1994-06-08 1996-05-22 Thermolase Corporation Skin surface peeling process using laser
US5522813A (en) * 1994-09-23 1996-06-04 Coherent, Inc. Method of treating veins
WO1996017656A1 (en) * 1994-12-09 1996-06-13 Cynosure, Inc. Near-infrared selective photothermolysis for vascular targets
US5531739A (en) * 1994-09-23 1996-07-02 Coherent, Inc. Method of treating veins
WO1996022813A1 (en) * 1995-01-27 1996-08-01 Candela Corporation Method for treating pigmentation abnormalities using pulsed laser radiation with an elongated cross section and apparatus for providing same
US5558667A (en) * 1994-12-14 1996-09-24 Coherent, Inc. Method and apparatus for treating vascular lesions
WO1996028998A2 (en) * 1994-10-13 1996-09-26 The General Hospital Corporation Two-pulse, lateral tissue illuminator
US5586981A (en) * 1994-08-25 1996-12-24 Xin-Hua Hu Treatment of cutaneous vascular and pigmented lesions
WO1997022384A1 (en) * 1995-12-18 1997-06-26 Laser Industries Ltd. Hair removal by selective photothermolysis with an alexandrite laser
WO1997045163A1 (en) * 1996-05-29 1997-12-04 Sls Biophile Limited Reduction of vascular blemishes by selective thermolysis
US5746735A (en) * 1994-10-26 1998-05-05 Cynosure, Inc. Ultra long pulsed dye laser device for treatment of ectatic vessels and method therefor
US5752949A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
US5752948A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
WO1998023329A1 (en) * 1996-11-25 1998-06-04 Rachel Lubart Device for light irradiation onto tissue
WO1998033558A1 (en) * 1997-02-05 1998-08-06 Candela Corporation Method and apparatus for treating wrinkles in skin using radiation
US5817089A (en) * 1991-10-29 1998-10-06 Thermolase Corporation Skin treatment process using laser
US5925035A (en) * 1991-10-29 1999-07-20 Thermolase Corporation Hair removal method
US6050990A (en) * 1996-12-05 2000-04-18 Thermolase Corporation Methods and devices for inhibiting hair growth and related skin treatments
US6152917A (en) * 1991-10-29 2000-11-28 Thermolase Corporation Hair removal device
WO2001074265A1 (en) * 2000-03-30 2001-10-11 Coherent, Inc. Dual-wavelength laser-treatment of vascular disorders
US6398801B1 (en) 1996-05-29 2002-06-04 Icn Photonics Limited Treatment of vascular lesions
WO2003057059A1 (en) * 2001-12-27 2003-07-17 Palomar Medical Technologies, Inc. Method and apparatus for improved vascular related treatment
US7255560B2 (en) 2002-12-02 2007-08-14 Nomir Medical Technologies, Inc. Laser augmented periodontal scaling instruments
WO2007118244A1 (en) * 2006-04-07 2007-10-18 The General Hospital Corporation Method and apparatus for producing thermal damage within the skin
US7470124B2 (en) 2003-05-08 2008-12-30 Nomir Medical Technologies, Inc. Instrument for delivery of optical energy to the dental root canal system for hidden bacterial and live biofilm thermolysis
US8496696B2 (en) 2006-04-12 2013-07-30 Lumenis Ltd. System and method for microablation of tissue
US8506979B2 (en) 2002-08-28 2013-08-13 Nomir Medical Technologies, Inc. Near-infrared electromagnetic modification of cellular steady-state membrane potentials
US8915948B2 (en) 2002-06-19 2014-12-23 Palomar Medical Technologies, Llc Method and apparatus for photothermal treatment of tissue at depth
US9028536B2 (en) 2006-08-02 2015-05-12 Cynosure, Inc. Picosecond laser apparatus and methods for its operation and use
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US10245107B2 (en) 2013-03-15 2019-04-02 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US10434324B2 (en) 2005-04-22 2019-10-08 Cynosure, Llc Methods and systems for laser treatment using non-uniform output beam
WO2020222810A1 (en) * 2019-04-30 2020-11-05 Candela Corrporation Pigment treatment system and methods of use thereof
EP3232239B1 (en) 2016-03-17 2022-07-06 Lyocon S.r.l. System for coupling a laser source in an optical guide
US11418000B2 (en) 2018-02-26 2022-08-16 Cynosure, Llc Q-switched cavity dumped sub-nanosecond laser
US11559354B2 (en) 2010-04-15 2023-01-24 Lumenis Be Ltd. System and method for microablation of tissue

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5697281A (en) * 1991-10-09 1997-12-16 Arthrocare Corporation System and method for electrosurgical cutting and ablation
US5697909A (en) * 1992-01-07 1997-12-16 Arthrocare Corporation Methods and apparatus for surgical cutting
US5871480A (en) * 1991-10-29 1999-02-16 Thermolase Corporation Hair removal using photosensitizer and laser
US5713845A (en) * 1991-10-29 1998-02-03 Thermolase Corporation Laser assisted drug delivery
US5891095A (en) * 1993-05-10 1999-04-06 Arthrocare Corporation Electrosurgical treatment of tissue in electrically conductive fluid
US5683366A (en) * 1992-01-07 1997-11-04 Arthrocare Corporation System and method for electrosurgical tissue canalization
US5681282A (en) * 1992-01-07 1997-10-28 Arthrocare Corporation Methods and apparatus for ablation of luminal tissues
US6210402B1 (en) 1995-11-22 2001-04-03 Arthrocare Corporation Methods for electrosurgical dermatological treatment
US5697882A (en) * 1992-01-07 1997-12-16 Arthrocare Corporation System and method for electrosurgical cutting and ablation
US6024733A (en) * 1995-06-07 2000-02-15 Arthrocare Corporation System and method for epidermal tissue ablation
US7429262B2 (en) * 1992-01-07 2008-09-30 Arthrocare Corporation Apparatus and methods for electrosurgical ablation and resection of target tissue
US6159194A (en) * 1992-01-07 2000-12-12 Arthrocare Corporation System and method for electrosurgical tissue contraction
US5902272A (en) * 1992-01-07 1999-05-11 Arthrocare Corporation Planar ablation probe and method for electrosurgical cutting and ablation
ES2040658B1 (en) * 1992-04-14 1994-05-16 Fernandez Rafael Julia CHROMOTHERAPY APPARATUS.
US5643252A (en) * 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
US5849035A (en) * 1993-04-28 1998-12-15 Focal, Inc. Methods for intraluminal photothermoforming
US6117109A (en) * 1995-11-22 2000-09-12 Arthrocare Corporation Systems and methods for electrosurgical incisions on external skin surfaces
US6749604B1 (en) 1993-05-10 2004-06-15 Arthrocare Corporation Electrosurgical instrument with axially-spaced electrodes
US5549596A (en) * 1993-07-07 1996-08-27 The General Hospital Corporation Selective laser targeting of pigmented ocular cells
EG20471A (en) 1993-07-12 1999-05-31 Thermotrex Corp Hair removal device and method
US6056738A (en) * 1997-01-31 2000-05-02 Transmedica International, Inc. Interstitial fluid monitoring
US5464436A (en) * 1994-04-28 1995-11-07 Lasermedics, Inc. Method of performing laser therapy
US5554153A (en) * 1994-08-29 1996-09-10 Cell Robotics, Inc. Laser skin perforator
US5611795A (en) * 1995-02-03 1997-03-18 Laser Industries, Ltd. Laser facial rejuvenation
US5879376A (en) * 1995-07-12 1999-03-09 Luxar Corporation Method and apparatus for dermatology treatment
US6161546A (en) * 1995-07-17 2000-12-19 Quardrivium, L.L.C. System for altering tissue beneath an outer layer of tissue
US6009876A (en) * 1997-05-20 2000-01-04 Yavitz; Edward Q. Method for modifying and reshaping collagen beneath the surface of skin
US7758537B1 (en) 1995-11-22 2010-07-20 Arthrocare Corporation Systems and methods for electrosurgical removal of the stratum corneum
US6461350B1 (en) 1995-11-22 2002-10-08 Arthrocare Corporation Systems and methods for electrosurgical-assisted lipectomy
US6228082B1 (en) 1995-11-22 2001-05-08 Arthrocare Corporation Systems and methods for electrosurgical treatment of vascular disorders
US6228078B1 (en) 1995-11-22 2001-05-08 Arthrocare Corporation Methods for electrosurgical dermatological treatment
US5846080A (en) * 1995-12-20 1998-12-08 W&H Dentalwerk Gmbh Laser dental devices and methods
US7229436B2 (en) * 1996-01-05 2007-06-12 Thermage, Inc. Method and kit for treatment of tissue
US7006874B2 (en) * 1996-01-05 2006-02-28 Thermage, Inc. Treatment apparatus with electromagnetic energy delivery device and non-volatile memory
US7473251B2 (en) * 1996-01-05 2009-01-06 Thermage, Inc. Methods for creating tissue effect utilizing electromagnetic energy and a reverse thermal gradient
US7267675B2 (en) * 1996-01-05 2007-09-11 Thermage, Inc. RF device with thermo-electric cooler
US7022121B2 (en) 1999-03-09 2006-04-04 Thermage, Inc. Handpiece for treatment of tissue
US7141049B2 (en) * 1999-03-09 2006-11-28 Thermage, Inc. Handpiece for treatment of tissue
US7189230B2 (en) 1996-01-05 2007-03-13 Thermage, Inc. Method for treating skin and underlying tissue
US20040000316A1 (en) * 1996-01-05 2004-01-01 Knowlton Edward W. Methods for creating tissue effect utilizing electromagnetic energy and a reverse thermal gradient
US7115123B2 (en) * 1996-01-05 2006-10-03 Thermage, Inc. Handpiece with electrode and non-volatile memory
US20030212393A1 (en) * 1996-01-05 2003-11-13 Knowlton Edward W. Handpiece with RF electrode and non-volatile memory
US5630811A (en) * 1996-03-25 1997-05-20 Miller; Iain D. Method and apparatus for hair removal
US5760395A (en) * 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5662644A (en) * 1996-05-14 1997-09-02 Mdlt, Inc. Dermatological laser apparatus and method
WO1997045164A1 (en) * 1996-05-28 1997-12-04 Kolomiitsev Alexei Konstantino Method for inhibiting of growth and preventing the formation of pigmental nevi on the skin
GB9618051D0 (en) 1996-08-29 1996-10-09 Sls Wales Ltd Wrinkle removal
US6214034B1 (en) 1996-09-04 2001-04-10 Radiancy, Inc. Method of selective photothermolysis
US5759200A (en) * 1996-09-04 1998-06-02 Azar; Zion Method of selective photothermolysis
US6190376B1 (en) * 1996-12-10 2001-02-20 Asah Medico A/S Apparatus for tissue treatment
US6312450B1 (en) 1997-05-20 2001-11-06 Natural Vision Center, Inc. System and method for improving the appearance of skin
EP0885629A3 (en) 1997-06-16 1999-07-21 Danish Dermatologic Development A/S Light pulse generating apparatus and cosmetic and therapeutic phototreatment
US5984915A (en) * 1997-10-08 1999-11-16 Trimedyne, Inc. Percutaneous laser treatment
US7276063B2 (en) * 1998-08-11 2007-10-02 Arthrocare Corporation Instrument for electrosurgical tissue treatment
US6059820A (en) 1998-10-16 2000-05-09 Paradigm Medical Corporation Tissue cooling rod for laser surgery
GB9905173D0 (en) * 1999-03-05 1999-04-28 Sls Biophile Limited Wrinkle reduction
US20020156471A1 (en) * 1999-03-09 2002-10-24 Stern Roger A. Method for treatment of tissue
US7041094B2 (en) * 1999-03-15 2006-05-09 Cutera, Inc. Tissue treatment device and method
US6383176B1 (en) 1999-03-15 2002-05-07 Altus Medical, Inc. Hair removal device and method
US6569155B1 (en) 1999-03-15 2003-05-27 Altus Medical, Inc. Radiation delivery module and dermal tissue treatment method
US6240925B1 (en) 1999-03-23 2001-06-05 Cynosure, Inc. Photothermal vascular targeting with bioreductive agents
CN1617689A (en) * 1999-06-30 2005-05-18 塞梅格公司 Fluid delivery apparatus
US6254594B1 (en) 1999-07-30 2001-07-03 Quadrivium, Llc Disposable light source for photothermal treatment of human tissue
US20020087155A1 (en) 1999-08-30 2002-07-04 Underwood Ronald A. Systems and methods for intradermal collagen stimulation
AU2003241638B2 (en) * 2000-02-03 2004-01-22 Gregg S. Homer Method for alteration of iris pigment
AU2001291157B2 (en) * 2000-02-03 2003-12-18 Gregg S. Homer Method for alteration of iris pigment
CA2397113A1 (en) * 2000-02-03 2001-08-09 Gregg S. Homer Method for alteration of iris pigmentation
US20070027446A1 (en) * 2000-02-22 2007-02-01 Rhytec Limited Method of removing a tattoo
US6979327B2 (en) * 2000-02-25 2005-12-27 Mount Sinai School Of Medicine Treatment of vitiligo
US6702838B1 (en) * 2000-09-18 2004-03-09 Lumenis Inc. Method of treating hypotrophic scars enlarged pores
US6808532B2 (en) * 2000-12-15 2004-10-26 Dan E. Andersen Laser treatment for reducing wrinkles
GB2370229A (en) * 2000-12-22 2002-06-26 Icn Photonics Ltd Light delivery system for improving the appearance of skin
US20040073199A1 (en) * 2001-02-02 2004-04-15 Homer Gregg S. Method for alteration of iris pigment
MXPA03006923A (en) * 2001-02-02 2003-11-18 Homer Gregg S Method for alteration of iris pigment.
US7018396B2 (en) * 2001-08-07 2006-03-28 New England Medical Center Hospitals, Inc. Method of treating acne
US7935139B2 (en) * 2001-12-10 2011-05-03 Candela Corporation Eye safe dermatological phototherapy
US7762965B2 (en) * 2001-12-10 2010-07-27 Candela Corporation Method and apparatus for vacuum-assisted light-based treatments of the skin
US7762964B2 (en) * 2001-12-10 2010-07-27 Candela Corporation Method and apparatus for improving safety during exposure to a monochromatic light source
JP4398252B2 (en) * 2001-12-10 2010-01-13 イノレーズ 2002 リミテッド Method and apparatus for improving safety while exposed to a monochromatic light source
EP1627662B1 (en) * 2004-06-10 2011-03-02 Candela Corporation Apparatus for vacuum-assisted light-based treatments of the skin
US20030109787A1 (en) * 2001-12-12 2003-06-12 Michael Black Multiple laser diagnostics
US20030109860A1 (en) * 2001-12-12 2003-06-12 Michael Black Multiple laser treatment
US20030216719A1 (en) * 2001-12-12 2003-11-20 Len Debenedictis Method and apparatus for treating skin using patterns of optical energy
US20040082940A1 (en) * 2002-10-22 2004-04-29 Michael Black Dermatological apparatus and method
US20080177359A1 (en) * 2002-05-03 2008-07-24 Advanced Light Technology, Llc. Differential photochemical and photomechanical processing
US7740600B2 (en) * 2002-08-02 2010-06-22 Candela Corporation Apparatus and method for inhibiting pain signals transmitted during a skin related medical treatment
US6991644B2 (en) * 2002-12-12 2006-01-31 Cutera, Inc. Method and system for controlled spatially-selective epidermal pigmentation phototherapy with UVA LEDs
US11007373B1 (en) * 2002-12-20 2021-05-18 James Andrew Ohneck Photobiostimulation device and method of using same
US20050177141A1 (en) * 2003-01-27 2005-08-11 Davenport Scott A. System and method for dermatological treatment gas discharge lamp with controllable current density
US20070265606A1 (en) * 2003-02-14 2007-11-15 Reliant Technologies, Inc. Method and Apparatus for Fractional Light-based Treatment of Obstructive Sleep Apnea
US20110040295A1 (en) * 2003-02-28 2011-02-17 Photometics, Inc. Cancer treatment using selective photo-apoptosis
US7354433B2 (en) * 2003-02-28 2008-04-08 Advanced Light Technologies, Llc Disinfection, destruction of neoplastic growth, and sterilization by differential absorption of electromagnetic energy
ES2441408T3 (en) 2003-03-27 2014-02-04 The General Hospital Corporation Device for dermatological treatment and fractional skin rejuvenation
JP2007531544A (en) * 2003-07-11 2007-11-08 リライアント・テクノロジーズ・インコーポレイテッド Method and apparatus for fractionated light treatment of skin
EP1651127B1 (en) 2003-07-16 2012-10-31 Arthrocare Corporation Rotary electrosurgical apparatus
US7291140B2 (en) * 2003-07-18 2007-11-06 Cutera, Inc. System and method for low average power dermatologic light treatment device
KR101160343B1 (en) * 2003-07-31 2012-06-26 젠틀웨이브즈 엘엘씨. System and method for the photodynamic treatment of burns, wounds, and related skin disorders
US7722600B2 (en) 2003-08-25 2010-05-25 Cutera, Inc. System and method for heating skin using light to provide tissue treatment
US8915906B2 (en) * 2003-08-25 2014-12-23 Cutera, Inc. Method for treatment of post-partum abdominal skin redundancy or laxity
US8870856B2 (en) * 2003-08-25 2014-10-28 Cutera, Inc. Method for heating skin using light to provide tissue treatment
US7326199B2 (en) * 2003-12-22 2008-02-05 Cutera, Inc. System and method for flexible architecture for dermatologic treatments utilizing multiple light sources
EP1742588B1 (en) * 2004-04-01 2016-10-19 The General Hospital Corporation Apparatus for dermatological treatment and tissue reshaping
US7704249B2 (en) * 2004-05-07 2010-04-27 Arthrocare Corporation Apparatus and methods for electrosurgical ablation and resection of target tissue
US7413572B2 (en) * 2004-06-14 2008-08-19 Reliant Technologies, Inc. Adaptive control of optical pulses for laser medicine
US7837675B2 (en) * 2004-07-22 2010-11-23 Shaser, Inc. Method and device for skin treatment with replaceable photosensitive window
US20060122584A1 (en) * 2004-10-27 2006-06-08 Bommannan D B Apparatus and method to treat heart disease using lasers to form microchannels
US8277495B2 (en) * 2005-01-13 2012-10-02 Candela Corporation Method and apparatus for treating a diseased nail
US20070176262A1 (en) * 2005-08-11 2007-08-02 Ernest Sirkin Series connection of a diode laser bar
US20070173799A1 (en) * 2005-09-01 2007-07-26 Hsia James C Treatment of fatty tissue adjacent an eye
WO2007038567A1 (en) * 2005-09-28 2007-04-05 Candela Corporation Treating cellulite
US20070083190A1 (en) * 2005-10-11 2007-04-12 Yacov Domankevitz Compression device for a laser handpiece
US7891362B2 (en) * 2005-12-23 2011-02-22 Candela Corporation Methods for treating pigmentary and vascular abnormalities in a dermal region
US20070212335A1 (en) * 2006-03-07 2007-09-13 Hantash Basil M Treatment of alopecia by micropore delivery of stem cells
US8460280B2 (en) * 2006-04-28 2013-06-11 Cutera, Inc. Localized flashlamp skin treatments
US8246611B2 (en) * 2006-06-14 2012-08-21 Candela Corporation Treatment of skin by spatial modulation of thermal heating
US20080082149A1 (en) * 2006-09-13 2008-04-03 Bernstein Eric F Laser treatment of pigmented lesions on the skin
EP2377482B1 (en) * 2006-09-29 2013-12-18 Candela Corporation A laser system for treatment of skin
US20080221649A1 (en) * 2007-03-09 2008-09-11 Agustina Echague Method of sequentially treating tissue
US20080269735A1 (en) * 2007-04-26 2008-10-30 Agustina Vila Echague Optical array for treating biological tissue
US7740651B2 (en) * 2007-09-28 2010-06-22 Candela Corporation Vacuum assisted treatment of the skin
US8920409B2 (en) * 2007-10-04 2014-12-30 Cutera, Inc. System and method for dermatological lesion treatment using gas discharge lamp with controllable current density
US8747400B2 (en) 2008-08-13 2014-06-10 Arthrocare Corporation Systems and methods for screen electrode securement
US8357150B2 (en) 2009-07-20 2013-01-22 Syneron Medical Ltd. Method and apparatus for fractional skin treatment
US8355799B2 (en) 2008-12-12 2013-01-15 Arthrocare Corporation Systems and methods for limiting joint temperature
US8317786B2 (en) 2009-09-25 2012-11-27 AthroCare Corporation System, method and apparatus for electrosurgical instrument with movable suction sheath
US8323279B2 (en) 2009-09-25 2012-12-04 Arthocare Corporation System, method and apparatus for electrosurgical instrument with movable fluid delivery sheath
US20110190745A1 (en) * 2009-12-04 2011-08-04 Uebelhoer Nathan S Treatment of sweat glands
US8696659B2 (en) 2010-04-30 2014-04-15 Arthrocare Corporation Electrosurgical system and method having enhanced temperature measurement
US9526556B2 (en) 2014-02-28 2016-12-27 Arthrocare Corporation Systems and methods systems related to electrosurgical wands with screen electrodes
US9649148B2 (en) 2014-07-24 2017-05-16 Arthrocare Corporation Electrosurgical system and method having enhanced arc prevention
US9597142B2 (en) 2014-07-24 2017-03-21 Arthrocare Corporation Method and system related to electrosurgical procedures
US11369802B2 (en) 2020-02-12 2022-06-28 Michael Barbour Methods and systems for the therapeutic application of laser and cannabidiol to the skin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2308554A1 (en) * 1973-02-21 1974-08-22 Nath Guenther DENTAL TREATMENT DEVICE FOR CARIES PROPHYLAXIS
WO1987004632A1 (en) * 1986-02-03 1987-08-13 Carl-Zeiss-Stiftung, Handelnd Als Carl Zeiss Device for therapeutical irradiation of organic tissue by laser radiation
EP0246552A2 (en) * 1986-05-21 1987-11-25 Hoechst Aktiengesellschaft Optical fibre comprising a liquid core and a cladding made of a synthetic fluoride material

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75998A0 (en) * 1984-08-07 1985-12-31 Medical Laser Research & Dev C Laser system for providing target tissue specific energy deposition
WO1986002783A1 (en) * 1984-10-25 1986-05-09 Candela Corporation Long pulse tunable dye laser

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2308554A1 (en) * 1973-02-21 1974-08-22 Nath Guenther DENTAL TREATMENT DEVICE FOR CARIES PROPHYLAXIS
WO1987004632A1 (en) * 1986-02-03 1987-08-13 Carl-Zeiss-Stiftung, Handelnd Als Carl Zeiss Device for therapeutical irradiation of organic tissue by laser radiation
EP0246552A2 (en) * 1986-05-21 1987-11-25 Hoechst Aktiengesellschaft Optical fibre comprising a liquid core and a cladding made of a synthetic fluoride material

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lasers in Surgery and Medicine vol. 1, 1981, USA & J.Parrish: "Microvasculature can be selectively damaged using dye lasers: a basic theorie and experimental evidence in human skin" *

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508209A2 (en) * 1991-03-27 1992-10-14 David G. Changaris Method of inducing tanning or DNA repair by pulsed radiation and apparatus to effect same
EP0508209B1 (en) * 1991-03-27 1997-12-29 David G. Changaris Apparatus for inducing tanning or DNA repair by pulsed radiation
US5752949A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
US6152917A (en) * 1991-10-29 2000-11-28 Thermolase Corporation Hair removal device
US6036684A (en) * 1991-10-29 2000-03-14 Thermolase Corporation Skin treatment process using laser
US5925035A (en) * 1991-10-29 1999-07-20 Thermolase Corporation Hair removal method
US5752948A (en) * 1991-10-29 1998-05-19 Thermolase Corporation Hair removal method
US5817089A (en) * 1991-10-29 1998-10-06 Thermolase Corporation Skin treatment process using laser
US5304170A (en) * 1993-03-12 1994-04-19 Green Howard A Method of laser-induced tissue necrosis in carotenoid-containing skin structures
EP0712322A1 (en) * 1994-06-08 1996-05-22 Thermolase Corporation Skin surface peeling process using laser
EP0712322A4 (en) * 1994-06-08 1996-10-23 Thermolase Corp Skin surface peeling process using laser
US5586981A (en) * 1994-08-25 1996-12-24 Xin-Hua Hu Treatment of cutaneous vascular and pigmented lesions
US5578029A (en) * 1994-09-23 1996-11-26 Coherent, Inc. Method of treating veins
US5531739A (en) * 1994-09-23 1996-07-02 Coherent, Inc. Method of treating veins
US5522813A (en) * 1994-09-23 1996-06-04 Coherent, Inc. Method of treating veins
WO1996028998A3 (en) * 1994-10-13 1996-11-28 Gen Hospital Corp Two-pulse, lateral tissue illuminator
US5632739A (en) * 1994-10-13 1997-05-27 The General Hospital Corporation Two-pulse, lateral tissue illuminator
US5776127A (en) * 1994-10-13 1998-07-07 The General Hospital Corporation Two-pulse, lateral tissue illuminator
WO1996028998A2 (en) * 1994-10-13 1996-09-26 The General Hospital Corporation Two-pulse, lateral tissue illuminator
US5746735A (en) * 1994-10-26 1998-05-05 Cynosure, Inc. Ultra long pulsed dye laser device for treatment of ectatic vessels and method therefor
US6391022B1 (en) 1994-10-26 2002-05-21 Cynosure, Inc. Ultra long pulsed dye laser device for treatment of ectatic vessels and method therefor
US6579284B2 (en) 1994-10-26 2003-06-17 Cynosure, Inc. Ultra long pulsed dye laser device for treatment of ectatic vessels and method therefor
CN1070714C (en) * 1994-12-09 2001-09-12 希诺索尔公司 Near-infrared selective photothermolysis for vascular tragets
WO1996017656A1 (en) * 1994-12-09 1996-06-13 Cynosure, Inc. Near-infrared selective photothermolysis for vascular targets
US5749868A (en) * 1994-12-09 1998-05-12 Cynosure, Inc. Near infra-red selective photothermolysis for ectatic vessels and method therefor
US5558667A (en) * 1994-12-14 1996-09-24 Coherent, Inc. Method and apparatus for treating vascular lesions
US5754573A (en) * 1994-12-14 1998-05-19 Coherent, Inc. Method and apparatus for treating vascular lesions
US5911718A (en) * 1994-12-14 1999-06-15 Coherent, Inc. Method and apparatus for treating vascular lesions
US5599342A (en) * 1995-01-27 1997-02-04 Candela Laser Corporation Method for treating pigmentation abnormalities using pulsed laser radiation with an elongated cross-section and apparatus for providing same
WO1996022813A1 (en) * 1995-01-27 1996-08-01 Candela Corporation Method for treating pigmentation abnormalities using pulsed laser radiation with an elongated cross section and apparatus for providing same
AU704892B2 (en) * 1995-12-18 1999-05-06 Laser Industries Ltd. Hair removal by selective photothermolysis with an alexandrite laser
US5879346A (en) * 1995-12-18 1999-03-09 Esc Medical Systems, Ltd. Hair removal by selective photothermolysis with an alexandrite laser
WO1997022384A1 (en) * 1995-12-18 1997-06-26 Laser Industries Ltd. Hair removal by selective photothermolysis with an alexandrite laser
US6398801B1 (en) 1996-05-29 2002-06-04 Icn Photonics Limited Treatment of vascular lesions
US6605083B2 (en) 1996-05-29 2003-08-12 Robert Marc Clement Reduction of vascular blemishes by selective thermolysis
WO1997045163A1 (en) * 1996-05-29 1997-12-04 Sls Biophile Limited Reduction of vascular blemishes by selective thermolysis
US6379376B1 (en) 1996-11-25 2002-04-30 Rachel Lubart Device for light irradiation onto tissue
WO1998023329A1 (en) * 1996-11-25 1998-06-04 Rachel Lubart Device for light irradiation onto tissue
US6162211A (en) * 1996-12-05 2000-12-19 Thermolase Corporation Skin enhancement using laser light
US6050990A (en) * 1996-12-05 2000-04-18 Thermolase Corporation Methods and devices for inhibiting hair growth and related skin treatments
WO1998033558A1 (en) * 1997-02-05 1998-08-06 Candela Corporation Method and apparatus for treating wrinkles in skin using radiation
WO2001074265A1 (en) * 2000-03-30 2001-10-11 Coherent, Inc. Dual-wavelength laser-treatment of vascular disorders
WO2003057059A1 (en) * 2001-12-27 2003-07-17 Palomar Medical Technologies, Inc. Method and apparatus for improved vascular related treatment
US8915948B2 (en) 2002-06-19 2014-12-23 Palomar Medical Technologies, Llc Method and apparatus for photothermal treatment of tissue at depth
US8506979B2 (en) 2002-08-28 2013-08-13 Nomir Medical Technologies, Inc. Near-infrared electromagnetic modification of cellular steady-state membrane potentials
US7255560B2 (en) 2002-12-02 2007-08-14 Nomir Medical Technologies, Inc. Laser augmented periodontal scaling instruments
US7470124B2 (en) 2003-05-08 2008-12-30 Nomir Medical Technologies, Inc. Instrument for delivery of optical energy to the dental root canal system for hidden bacterial and live biofilm thermolysis
US10434324B2 (en) 2005-04-22 2019-10-08 Cynosure, Llc Methods and systems for laser treatment using non-uniform output beam
EP2578175A3 (en) * 2006-04-07 2013-05-01 The General Hospital Corporation Method and apparatus for producing thermal damage within the skin
WO2007118244A1 (en) * 2006-04-07 2007-10-18 The General Hospital Corporation Method and apparatus for producing thermal damage within the skin
US8496696B2 (en) 2006-04-12 2013-07-30 Lumenis Ltd. System and method for microablation of tissue
US10687893B2 (en) 2006-04-12 2020-06-23 Lumenis Ltd. System and method for microablation of tissue
US10849687B2 (en) 2006-08-02 2020-12-01 Cynosure, Llc Picosecond laser apparatus and methods for its operation and use
US9028536B2 (en) 2006-08-02 2015-05-12 Cynosure, Inc. Picosecond laser apparatus and methods for its operation and use
US11712299B2 (en) 2006-08-02 2023-08-01 Cynosure, LLC. Picosecond laser apparatus and methods for its operation and use
US10966785B2 (en) 2006-08-02 2021-04-06 Cynosure, Llc Picosecond laser apparatus and methods for its operation and use
US9919168B2 (en) 2009-07-23 2018-03-20 Palomar Medical Technologies, Inc. Method for improvement of cellulite appearance
US11559354B2 (en) 2010-04-15 2023-01-24 Lumenis Be Ltd. System and method for microablation of tissue
US10581217B2 (en) 2012-04-18 2020-03-03 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US11095087B2 (en) 2012-04-18 2021-08-17 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US11664637B2 (en) 2012-04-18 2023-05-30 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US9780518B2 (en) 2012-04-18 2017-10-03 Cynosure, Inc. Picosecond laser apparatus and methods for treating target tissues with same
US10305244B2 (en) 2012-04-18 2019-05-28 Cynosure, Llc Picosecond laser apparatus and methods for treating target tissues with same
US10245107B2 (en) 2013-03-15 2019-04-02 Cynosure, Inc. Picosecond optical radiation systems and methods of use
US11446086B2 (en) 2013-03-15 2022-09-20 Cynosure, Llc Picosecond optical radiation systems and methods of use
US10765478B2 (en) 2013-03-15 2020-09-08 Cynosurce, Llc Picosecond optical radiation systems and methods of use
US10285757B2 (en) 2013-03-15 2019-05-14 Cynosure, Llc Picosecond optical radiation systems and methods of use
EP3232239B1 (en) 2016-03-17 2022-07-06 Lyocon S.r.l. System for coupling a laser source in an optical guide
US11418000B2 (en) 2018-02-26 2022-08-16 Cynosure, Llc Q-switched cavity dumped sub-nanosecond laser
US11791603B2 (en) 2018-02-26 2023-10-17 Cynosure, LLC. Q-switched cavity dumped sub-nanosecond laser
WO2020222810A1 (en) * 2019-04-30 2020-11-05 Candela Corrporation Pigment treatment system and methods of use thereof
US11730538B2 (en) 2019-04-30 2023-08-22 Candela Corporation Pigment treatment system and methods of use thereof

Also Published As

Publication number Publication date
AU7562591A (en) 1991-10-10
AU7463991A (en) 1991-10-10
EP0519964A1 (en) 1992-12-30
EP0519964B1 (en) 1994-08-10
WO1991013653A1 (en) 1991-09-19
IL97553A0 (en) 1992-06-21
US5312395A (en) 1994-05-17
JPH05505737A (en) 1993-08-26
DE69103409T2 (en) 1995-03-23
DE69103409D1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
WO1991013652A1 (en) Apparatus for treating abnormal pigmentation of the skin
CA2326120C (en) Method and apparatus for the selective targeting of lipid-rich tissues
Taylor et al. Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser
US6613040B2 (en) Twin light laser
Patil Overview of lasers
CA2171260C (en) Method and apparatus for depilation using pulsed electromagnetic radiation
Ross et al. Intense pulsed light and laser treatment of facial telangiectasias and dyspigmentation: some theoretical and practical comparisons
US5599342A (en) Method for treating pigmentation abnormalities using pulsed laser radiation with an elongated cross-section and apparatus for providing same
Ross Laser versus intense pulsed light: competing technologies in dermatology
EP0172490A1 (en) Laser system for providing target specific energy deposition and damage
Reichert Evaluation of the long-pulse dye laser for the treatment of leg telangiectasias
CA2251555A1 (en) Alexandrite laser system for treatment of dermatological specimens
US20080200908A1 (en) Light beam wavelength mixing for treating various dermatologic conditions
Bahmer et al. Recommendation for laser and intense pulsed light (IPL) therapy in dermatology
Brazzini et al. Laser tissue interaction in epidermal pigmented lesions
Lipp et al. Intense pulsed light: a methodical approach to understanding clinical endpoints
US20080255639A1 (en) Method and device for treating tissue using a coagulated beam path
Lou et al. Dermatologic laser surgery
O’Connor et al. Understanding Lasers, Light Sources, and Other Energy-Based Technology
Boechat et al. Lasers, Lights, and Related Technologies in Cosmetic Dermatology
Chan Treatment of photoaging in Asian skin
Jovanovic et al. Ablation of dermal and mucosal lesions with a new CO2 laser application system
Fitzpatrick et al. Tattoo removal with the alexandrite laser: a clinical and histologic study
Tan et al. The pulsed tunable dye laser for benign vascular lesions
Lanigan Recent advances in the use of lasers in dermatology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE